BAYER AG
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants
Phase 1
Completed
- Conditions
- Overactive BladderDiabetic Neuropathic PainRefractory or Unexplained Chronic CoughEndometriosis Related Pain
- Interventions
- Drug: Matching Placebo
- First Posted Date
- 2020-02-12
- Last Posted Date
- 2023-01-26
- Lead Sponsor
- Bayer
- Target Recruit Count
- 36
- Registration Number
- NCT04265781
- Locations
- 🇯🇵
Hakata Clinic, Fukuoka, Japan
Study to Find Out How Long it Takes Azelastine Hydrochloride 0.15% Nasal Spray to Relieve Symptoms in Patients Suffering From Allergic Rhinitis
Phase 3
Completed
- Conditions
- Allergic Rhinitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2022-03-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 110
- Registration Number
- NCT04264637
- Locations
- 🇨🇦
Cliantha Research, Mississauga, Ontario, Canada
PRECISE, a Study to Gather More Information About Bone Fractures and Survival in Castration-resistant PRostate Cancer (CRPC) patiEnts Treated With Radium-223 in Routine Clinical practIce in SwedEn
Completed
- Conditions
- Metastatic Castration-Resistant Prostate Cancer
- Interventions
- Drug: Other standard care
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1434
- Registration Number
- NCT04256993
- Locations
- 🇸🇪
Database Study, Database Study, Sweden
Study to Learn the Effect of Drug BAY1817080 on the Way the Body Absorbs, Distributes and Excretes Another Drug Rosuvastatin in Healthy Adult Participants
Phase 1
Completed
- Conditions
- Drug Interactions
- Interventions
- First Posted Date
- 2020-02-05
- Last Posted Date
- 2021-03-11
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT04252300
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Daytona Beach, Florida, United States
Study to Gather Information About the Safety of Oral Anticoagulation Drugs and How Well These Drugs Work in Real World for Patients With Non-valvular Atrial Fibrillation (Irregularly Heart Beats Which is Not Caused by a Heart Valve Problem)
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- First Posted Date
- 2020-01-31
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Bayer
- Target Recruit Count
- 134897
- Registration Number
- NCT04249401
- Locations
- 🇸🇪
Many locations, Multiple Locations, Sweden
Study on the Safety of Drug BAY2586116 and How it Works in Patients With Obstructive Sleep Apnea (a Sleep Disorder Caused by the Narrowing and Collapse of the Airway During Sleep) Including the Blood Level of the Drug and Effect of Its Doses and Routes of Administration
Phase 2
Completed
- Conditions
- Sleep Apnea, Obstructive
- Interventions
- Drug: BAY2586116 (A1)Drug: Placebo (A2)Drug: BAY2586116 (B1)Drug: BAY2586116 (B2)Drug: BAY2586116 (B3)Drug: BAY2586116 (C)
- First Posted Date
- 2020-01-22
- Last Posted Date
- 2022-08-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 14
- Registration Number
- NCT04236440
- Locations
- 🇦🇺
Adelaide Institute for Sleep Health, Bedford Park, South Australia, Australia
Study to Gather Information on the Safety and How Radium-223 Dichloride, an Alpha Particle-emitting Radioactive Agent, Works Under Routine Clinical Practice in Taiwan in Patients With Castration-resistant Prostate Cancer (CRPC) Which Has Spread to the Bone
Completed
- Conditions
- Castration-resistant Prostate Cancer
- Interventions
- First Posted Date
- 2020-01-18
- Last Posted Date
- 2024-07-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 194
- Registration Number
- NCT04232761
- Locations
- 🇨🇳
Many locations, Multiple Locations, Taiwan
Study to Gather Information About the Proper Dosing of the Oral FXIa Inhibitor BAY 2433334 and to Compare the Safety of the Study Drug to Apixaban, a Non-vitamin K Oral Anticoagulant (NOAC) in Patients With Irregular Heartbeat (Atrial Fibrillation) That Can Lead to Heart-related Complications.
Phase 2
Completed
- Conditions
- Atrial Fibrillation (AF)
- Interventions
- First Posted Date
- 2020-01-06
- Last Posted Date
- 2022-10-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 755
- Registration Number
- NCT04218266
- Locations
- 🇫🇷
Hôpital de Rangueil - Toulouse, Toulouse, France
🇪🇸Hospital Universitario 12 de Octubre, Madrid, Spain
🇸🇪Danderyds sjukhus, Stockholm, Sweden
Survey on Belgian Patients Suffering From Irregular Heartbeat and Starting Treatment With a Drug to Prevent Blood Clots in Blood Vessels and the Heart. This Study is Also Called BELANCOS.
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- Other: Questionnaires
- First Posted Date
- 2019-12-03
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Bayer
- Target Recruit Count
- 164
- Registration Number
- NCT04183270
- Locations
- 🇧🇪
Many locations, Multiple Locations, Belgium
Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment
Completed
- Conditions
- Non-valvular Atrial Fibrillation
- Interventions
- First Posted Date
- 2019-11-22
- Last Posted Date
- 2024-10-18
- Lead Sponsor
- Bayer
- Target Recruit Count
- 812
- Registration Number
- NCT04174859
- Locations
- 🇮🇹
Many locations, Multiple Locations, Italy
© Copyright 2025. All Rights Reserved by MedPath